HD Insights: Volume 13

HD Insights: Volume 13

HD Insights Volume 13 (PDF)

April 23rd, 2016 Heather Hare To read a non-PDF version of HD Insights Vol. 13, click here.

Highlights of HSG 2015

February 16th, 2016 Heather Hare The Huntington Study Group held their 22nd Annual Meeting and the 9th Annual Clinical Research Symposium October 21−24, in Tampa Bay, FL. By: George McNally, BMedSc HSG 2015 provided a platform for the world’s leading HD experts, clinicians, scientists, and the HD community to discuss the most promising and latest innovations in HD research. Chaired
+ Read More

Genetic factors that modify clinical onset of HD

February 16th, 2016 Heather Hare By: Jong-Min Lee, PhD on behalf of the Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium HD is due to a dominantly inherited CAG trinucleotide repeat expansion in the HTT gene that is both necessary and sufficient to cause clinical manifestations. The size of the expanded CAG repeat largely determines the rate of the pathogenic process
+ Read More

Meet the Partner

February 16th, 2016 Heather Hare VITAL SIGNS NAME: Scott Schobel, MD, MS TITLE: Translational Medicine Leader, Hoffmann-La Roche Pharmaceuticals EDUCATION: BA, Japanese, University of Minnesota; MD, University of North Carolina-Chapel Hill; MS, Columbia University Mailman School of Public Health HOBBIES: Skiing; studying languages (currently German); chasing after his three sons Dr. Scott Schobel, former Professor of Psychiatry at Columbia University
+ Read More

Antisense Oligonucleotides Enter Clinical Trials

February 16th, 2016 Heather Hare VITAL SIGNS NAME: Ionis Pharmaceuticals STOCK SYMBOL: IONS    SHARE PRICE AS OF 2/5/16: $35.25 MARKET CAPITALIZATION: $4.24 billion EMPLOYEES: 390 HEADQUARTERS: Carlsbad, CA Meet the team behind IONIS-HTTRx, the antisense oligonucleotide therapy with the potential to transform HD treatment Ionis Pharmaceuticals has been developing antisense-based therapies for a variety of conditions since 1989. The company has developed an antisense oligonucleotide (ASO) that targets huntingtin messenger
+ Read More

Research Round-Up

February 16th, 2016 Heather Hare By: Lise Munsie, PhD In the lab… The Ranum laboratory published their discovery of Repeat Associated Non-ATG (RAN) translation in HD in Neuron.1 This was the first demonstration of RAN translation in a disease where the causative triplet repeat expansion occurs in the coding region. They showed that poly-Ala, poly-Cys, poly-Leu and poly-Ser proteins are
+ Read More

Highly Cited HD Research

February 16th, 2016 Heather Hare In this edition of HD Insights, we take a look at some of the most impactful HD research articles of 2014. We searched Thomson Reuters’ “Web of Science” service in December 2015 and identified five papers as the most highly cited original research articles on HD published in 2014. Reviews and book chapters were excluded,
+ Read More

Editor’s Letter

February 16th, 2016 Heather Hare Welcome to the thirteenth edition of HD Insights, timed for release at the beginning of the 11th Annual CHDI HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate, and facilitate research in HD, and grateful to our subscribers, our editorial board, and our sponsors for their generous support of the periodical. 
+ Read More